Kezar Life Sciences Inc. (KZR) provides real-time updates and accurate data to help investors navigate the market effectively. Despite significant losses, analysts still forecast a positive outlook for the company’s future with a target price of $16.67. KZR’s equity return currently stands at -25.20%, with -23.30% for asset returns. Morningside Venture Investment, the 10% owner of KZR, sold 25,000 shares at $7.15 back in Feb 03, 2023, and now holds 5,487,993 shares at $178,650 based on the most recent closing price. The stock is currently trading far below its 50-day moving average and 52-week high. It is also worth noting that KZR’s liquidity ratio stands at 25.98.
Kezar Life Sciences Inc. (NASDAQ: KZR) has recently undergone significant price decreases, with the stock falling by -29.34% in the past week, -44.96% over the last month, and -48.01% over the past quarter. The company’s volatility ratio for the week is 10.39%, while the volatility levels for the last 30 days are 7.61%.
Price Forecast and Stock Details
Despite these losses, analysts forecast an average price point of $16.67 for Kezar Life Sciences Inc. (KZR), which is $13.84 higher than the current market price. The public float for KZR stands at 51.63M, and short sellers currently hold an 8.36% ratio of that float. On March 22, 2023, the average trading volume for KZR was 696.01K shares.
Latest Price Update and Analysts’ Opinion
On March 22, 2023, Kezar Life Sciences Inc. (KZR)’s stock price experienced a slight decrease of -0.27 compared to its previous closing price of 3.67. Despite this, the company’s latest stock prices show a -29.34% decline over the last five trading sessions. According to Wells Fargo’s research note, they have provided a “Overweight” rating for KZR stocks and expect to see the company reach a price target of $19.
Trading and Insider Activity
KZR is currently trading at -40.50% from the 50-Day Moving Average, with volatility rates increasing by 10.39% in the past 30 days. Over the last 20 days, the simple moving average for the company’s stock was -31.89%, while the simple moving average for the last 200 days was -52.18%. Furthermore, insider trading reports show that Morningside Venture Investment sold 40,000 shares at the price of $6.88 back on Feb 06, with a current ownership of 5,447,993 shares valued at $275,320 using the latest closing price.
In conclusion, Kezar Life Sciences Inc. (KZR) provides real-time updates and accurate data to help investors navigate the market effectively. While the stock has undergone significant losses, analysts still forecast a positive outlook for the company’s future with a target price of $16.67.
Kezar Life Sciences Inc. (KZR) Insider Trading and Stock Fundamentals Update
Morningside Venture Investment, the 10% owner of Kezar Life Sciences Inc., sold 25,000 shares at $7.15 during a trade back on Feb 03, 2023. As a result, Morningside Venture Investment now holds 5,487,993 shares at $178,650 based on the most recent closing price.
Stock Fundamentals for KZR
KZR’s equity return currently stands at -25.20, with -23.30 for asset returns. The company’s liquidity ratio is also of interest to investors, standing at 25.98.
In conclusion, Kezar Life Sciences Inc. (KZR) has experienced a downturn in recent times. However, analysts still hold a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth noting that the stock is currently trading far below its 50-day moving average and 52-week high.
Don’t miss interesting posts on Famousbio
